CAR T cell therapy could be a highly effective tool against atherosclerosis, a common condition that leads to heart attacks and stroke.
In a historic medical breakthrough, a child with a rare genetic disorder has been successfully treated with a customized CRISPR gene editing therapy.
Robert Vonderheide, MD, DPhil, director of the Abramson Cancer Center, will be the 2026-2027 President-Elect for the American Association for Cancer Research.
After five years, the Lead-Free Families initiative is proving the impact of a health system investing in safe homes.
CAREs grant recipients are translating expertise into action—expanding science education, supporting early literacy, and strengthening volunteer-led service efforts.
A clinical psychologist says public disclosures of sexual trauma can inspire difficult conversations about treatment for others.
Researchers will develop advanced imaging methods for the liver and intestinal lymphatic system with an $8 million grant.
Public investments in biomedical research have an outsized effect, driving new scientific insights, economic growth, and ultimately treatments and cures.
The successes of CAR T research show the importance of the cycle of science—sparking new ideas and clinical trials that give patients better options.
The Penn Medicine Co-Investment program spurs faculty innovation, creates jobs, and helps scale up ideas into large-scale clinical studies.
New clues in pancreas lymph nodes and spleen could stop the disease before insulin is lost forever.
A reimagined facility has been introduced as the epicenter for pioneering Penn research aimed at “breaking the immunological code” of autoimmune diseases and bringing them to heel.
Penn Medicine research is bringing the “sleeper” phase of cancer to light—creating hope that more cancers could be wiped out for good and never come back.
Lung tumors can signal the brain to make it activate nerves that quiet immune cell activity near the tumor, new research shows. Disrupting this “tumor-brain axis” led to better anticancer immunity and slower tumor growth in animal models. — Feb. 4, 2026
A more focused CAR T strategy for B-cell cancers targeting a new receptor protein could be effective in B-cell cancers and lupus while leaving normal B-cells alone, unlike current treatments, Penn Medicine researchers demonstrated. — Feb. 4, 2026
Messenger-RNA vaccines work well against a virus because they cause viral proteins to be made in the patient’s own cells, simulating an infection. Penn Medicine researchers detailed how the lipids that encapsulate mRNA in the vaccines play an important role. — Dec. 24, 2025
Clinical research professionals’ quiet work with patients and data behind the scenes is vital to moving innovative research forward.
A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer.
Carl June, MD, explains how CAR T cell therapy, which has been transformative for blood cancers, holds the potential to help millions more patients.
Bilateral hand transplant at Penn Medicine gives Swiss man new hands 16 years after childhood amputations.
Uterus transplant is still a rare procedure—but for the six moms who have had eight babies to date through Penn’s program, it means the world.
In a proof of concept for a future bridge to transplant, researchers circulated a deceased donor’s blood through a genetically engineered pig liver.
Every minute in the U.S., a woman needs a blood transfusion due to her period. Kathleen O’Neill, MD, is working to develop a novel therapy to protect women.
Could the mRNA technology behind COVID vaccines be used to tamp down the immune system for celiac and other autoimmune diseases?
Biomedical innovations using mRNA could prevent, treat, or cure numerous diseases. Penn Medicine is advancing its Nobel Prize-winning technology worldwide.
The Basser Center for BRCA is running an innovative cancer interception clinical trial that depends on volunteers with deep, personal ties to cancer.
Penn Medicine researchers are at the forefront of new scientific efforts to interrupt the development of cancer at its earliest stages.
The gift from Penn alumni Mindy and Jon Gray establishes the Basser Cancer Interception Institute to stop hereditary cancers at the earliest stages.
